News & Views

  • Kayentis Opens Japanese Subsidiary to Support Growth of Asia-Pacific Clinical Trials Sector
  • Guillaume Juge

Kayentis Opens Japanese Subsidiary to Support Growth of Asia-Pacific Clinical Trials Sector

Nov 20 2019 Read 816 Times

Kayentis, a global provider of eCOA (electronic Clinical Outcome Assessment) solutions for clinical trials, has announced the opening of a subsidiary in Japan, the world’s third largest pharmaceutical market, where
clinical developments have been expanding. Based in Tokyo, the subsidiary will enable Kayentis to meet the logistical requirements of multi-national studies taking place in Asia-Pacific and cater to the needs of local CROs for digital data collection services with custom geographic capabilities.

Kayentis, which specialises in eCOA solutions for phases IIB/III, has been collaborating with local CRO partners in Japan since 2017. As many as 75% of the clinical trial studies conducted by Kayentis include populations from Asia-Pacific.

“The Japanese and the wider Asia-Pacific clinical trials market is important to us. Kayentis already has customers in the region. We are thrilled to be opening a subsidiary in Tokyo, where we will be able to offer closer support to our customers running trials in Asia,” said Guillaume Juge, CEO of Kayentis. “This expansion comes amid the release of our eCOA solution - Clin’form3 - available in Japanese. It brings new design improvements that save time during the set-up stages of the study. We anticipate that the easier integration of medical device data and reporting enhancements will be of great benefit to clients in this strategic market.”

The Japanese eCOA sector is growing. Industry Research forecasts that the global ePRO, E-Patient Diaries and eCOA market is expected to grow at an exponential CAGR of 15.3%, rising to a value of just under $958M (€861.8M) in 2017 to reach approximately $2,986M (€2,686M) in 2025.

Richard Triepel, Business Development Director for Asia-Pacific at Kayentis, who has lived and worked in Japan for 14 years, will lead activities at the Tokyo-based subsidiary when it becomes operational in January 2020.
 

Reader comments

Do you like or dislike what you have read? Why not post a comment to tell others / the manufacturer and our Editor what you think. To leave comments please complete the form below. Providing the content is approved, your comment will be on screen in less than 24 hours. Leaving comments on product information and articles can assist with future editorial and article content. Post questions, thoughts or simply whether you like the content.

Post a Comment




Digital Edition

Lab Asia December 2019

December 2019

In This Edition Mass Spectrometry & Spectroscopy - Translating Proteomic MALDi Tissue Typing to Clinical Pathology - Fusion Protein Complexes Analysed by CG-MALS - Non-equivalent, Multivalen...

View all digital editions

Events

SLAS 2020

Jan 25 2020 San Diego, CA, USA

Arab Health

Jan 27 2020 Dubai, UAE

Nano Tech 2020

Jan 29 2020 Tokyo, Japan

HTC-16

Jan 29 2020 Ghent, Belgium

MEDLAB MIDDLE EAST

Feb 03 2020 Dubai, UAE

View all events